Experimental use of estriol for visualizing the vitreous body in the anterior chamber after posterior capsule rupture in animal models.
To compare the efficacy and safety of estriol and triamcinolone acetonide suspensions in visualizing the prolapsed vitreous body in the anterior chamber after posterior capsule rupture in animal models. Tsukuba University Institute of Clinical Medicine, Ibaraki, Japan. To evaluate efficacy, triamcinolone acetonide or estriol suspension was injected into the anterior chambers of porcine eyes after intentional posterior capsule rupture. To evaluate safety, triamcinolone acetonide 5.0 mg or estriol in 0.1 mL suspension was injected into the anterior chamber of New Zealand white rabbits. Slitlamp examinations, intraocular pressure (IOP), corneal endothelial cell density (ECD) measurements, and histologic examinations were performed up to 28 days after the injection. Triamcinolone acetonide and estriol were equally effective in allowing visualization of the prolapsed vitreous body in the anterior chamber. The granules of triamcinolone acetonide or estriol disappeared 1 day after the injection and did not affect the IOP or corneal ECD. No statistically significant histological changes were observed in the eyes 28 days after the injection of triamcinolone acetonide or estriol. Estriol was effective for the visualization of the prolapsed vitreous body in the anterior chamber after posterior capsule rupture. In experimental models, no significant side effects were observed after the injection of estriol in the anterior chamber. Results suggest that estriol is an alternative reagent for visualizing the vitreous body, especially in steroid responders, because it has no glucocorticoid or mineralocorticoid activity.